ArticleScientific reports2026
Clinicoradiological differentiation of TERT promoter-mutant molecular glioblastoma versus histological glioblastoma: a single-center cohort study of 105 IDH-wildtype tumors.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To compare the clinicopathological and magnetic resonance imaging (MRI) characteristics and prognostic implications between molecular glioblastoma (mol-GBM) and histological glioblastoma (hist-GBM) according to the 2021 WHO classification of central nervous system tumors (CNS5), we conducted a retrospective study of 105 patients with IDH-wildtype gliomas diagnosed between 2016 and 2022. Patients were reclassified into hist-GBM (n = 70) and mol-GBM (n = 35), with mol-GBM defined by TERT promoter mutation. Comparative analyses of clinical, molecular, and radiological features were performed. Overall survival (OS) was assessed in a subgroup of 96 patients using Kaplan-Meier and multivariable Cox regression models. Patients with mol-GBM were significantly younger (median age: 53 vs. 55.5 years, p = 0.046, median difference = - 2.5, 95% CI: -7.434 to 2.434), exhibited lower Ki-67 proliferation indices (30 vs. 40%, p = 0.002, median difference = - 10.0, 95% CI: -16.638 to - 3.362), and had lower p53 mutation rates (65.6 vs. 84.1%, p = 0.040, OR = 0.367, 95% CI: 0.138 to 0.973). MRI analysis demonstrated that mol-GBM was associated with less extensive peritumoral edema (major edema: 54.3 vs. 68.6%; p = 0.006) and lower tumor heterogeneity grades (Grade 3: 20.0% vs. 44.2%, p = 0.001, OR = 4.360, 95% CI: 1.950 to 9.746). No significant differences were observed in quantitative enhancement parameters or apparent diffusion coefficient (ADC) values. Survival analysis revealed a non-significant trend toward improved OS in the mol-GBM group (median OS: 17.0 vs. 13.0 months, log-rank p = 0.091). In multivariable analysis, GBM subtype was not an independent predictor of survival (hazard ratio [HR] = 0.829, 95% confidence interval [CI]: 0.432 to 1.591, p = 0.573). In conclusion, TERT promoter-mutant mol-GBM is characterized by a distinct clinicoradiological profile, including younger age at diagnosis and less aggressive imaging features. While these findings may aid preoperative suspicion, they do not confer independent prognostic value, underscoring the necessity of integrated molecular diagnosis to ensure appropriate treatment intensity and prevent undertreatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.